Cyclosporin (CsA) is currently the main immunosuppressive agent used in organ transplantation with considerable improvement in graft survival. Oral CsA solution is highly lipophilic, and its bioavailability may be reduced in cystic fibrosis (CF) heart-lung transplant recipients with pancreatic, gas
Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome
โ Scribed by Tan, Keith K C; Trull, Andrew K; Hue, Karen L; Best, Nicola G; Wallwork, John; Higenbottam, Tim W
- Book ID
- 109845296
- Publisher
- Nature Publishing Group
- Year
- 1993
- Tongue
- English
- Weight
- 845 KB
- Volume
- 53
- Category
- Article
- ISSN
- 0009-9236
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Patients with cystic fibrosis absorb cyclosporin poorly and erratically. We have compared the relative bioavailability of cyclosporin from conventional and microemulsion formulations in 5 adult heart-lung transplant candidates with cystic fibrosis. Relative bioavailability was compared at two dose l
Pharmacokinetic profiles were obtained for 16 heart or lung recipients following the administration of identical doses of cyclosporin as oral solution and capsules on consecutive days. A comparison of pharmacokinetic parameters (AUC, Cmax, Cmi n and tmax) showed that there were no significant differ